StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Stock analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the company. JMP Securities reaffirmed a “market outperform” rating and set a $6.00 target price on shares of Cellectis in a report on Friday, May 31st. Oppenheimer cut their target price on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, June 12th.

Cellectis Trading Up 0.9 %

NASDAQ CLLS opened at $2.21 on Thursday. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. Cellectis has a twelve month low of $0.96 and a twelve month high of $3.77. The company has a market cap of $122.84 million, a price-to-earnings ratio of -1.71 and a beta of 3.09. The business’s fifty day moving average is $2.21 and its 200 day moving average is $2.41.

Cellectis (NASDAQ:CLLS) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.05. The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. As a group, sell-side analysts expect that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CLLS. XTX Topco Ltd bought a new position in shares of Cellectis in the 2nd quarter worth about $29,000. Principal Financial Group Inc. raised its position in shares of Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after acquiring an additional 12,467 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after acquiring an additional 10,605 shares in the last quarter. Finally, Long Focus Capital Management LLC raised its position in shares of Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.